drugset / Trial / NCT00208520

Second-Line Treatment Choice for Epilepsy

NCT00208520

Unknown 60 enrolled Dutch Epilepsy Clinics Foundation
RandomizedParallel-groupOpen-labelTreatment

Summary

Most patients are prescribed valproate as their first antiepileptic drug. It is unknown which is the best second-line drug when patients do not become seizure free on valproate. This has led the Dutch Epilepsy Clinics Foundation (SEIN) to start the SLICE study. Adult patients with partial and/or tonic-clonic seizures, insufficiently responding to valproate, are recruited for this study. These patients are randomized to receive one of three other drugs. Patients wil initially use this drug next to valproate. Neurologists of more than 20 general hospitals en neurologists of SEIN are participating in this study.

Timeline

Start
2003-07
Primary completion
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule
Subject Lamotrigine Small molecule
Subject Levetiracetam Other / unclassified

Indications